Literature DB >> 19550211

p16 Improves interobserver agreement in diagnosis of anal intraepithelial neoplasia.

Sarah M Bean1, Regina S Meara, Robin T Vollmer, Michael G Conner, D Ralph Crowe, Lea Novak, Isam A Eltoum, Stanley J Robboy, David C Chhieng.   

Abstract

OBJECTIVES: Evaluation of anal intraepithelial neoplasia (AIN) is subjective. Previous studies have shown p16 and Ki-67 expressions to correlate with AIN grade. Biomarkers like p16 and Ki-67 may improve interobserver agreement. The objectives were (1) to determine the extent of interobserver agreement in evaluating AIN on routine hematoxylin and eosin (H&E) sections and (2) to test whether p16 and/or Ki-67 staining improve interobserver diagnostic agreement.
MATERIALS AND METHODS: Seventy-seven anal specimens were retrieved. Sections were stained with monoclonal antibodies against p16 and Ki-67. Blind to the original diagnoses, 4 pathologists assessed H&E alone, p16 alone, Ki-67 alone, and all 3 simultaneously. Diagnoses were normal/reactive, AIN I/HPV, AIN II, and AIN III. Agreement was calculated using kappa and S statistics.
RESULTS: Pathologists were board certified and had 2 to 25 years (mean = 13.6 years) of experience. Fair agreement was observed using H&E diagnosis alone (kappa = 0.38, S = 0.56). The p16 diagnostic evaluation demonstrated the highest agreement (kappa = 0.57, S = 0.73). Interobserver agreement for Ki-67 alone and for H&E/p16/Ki-67 combined were comparable to that of H&E alone (kappa = 0.4, S = 0.54 and kappa = 0.44, S = 0.62, respectively). When the pathologists' diagnoses for all diagnostic evaluations were compared with consensus diagnoses, the lowest average magnitude of disagreement was seen with Ki-67 alone, followed by p16 alone, H&E/p16/Ki-67 combined, and H&E alone.
CONCLUSIONS: Interobserver agreement for diagnosis of AIN was fair when based solely on H&E preparation. p16 alone improved interobserver agreement and demonstrated superior agreement when compared with H&E, Ki-67, and H&E/p16/Ki-67 combined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19550211     DOI: 10.1097/LGT.0b013e3181934486

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  6 in total

1.  Histological features associated with diagnostic agreement in atypical ductal hyperplasia of the breast: illustrative cases from the B-Path study.

Authors:  Kimberly H Allison; Mara H Rendi; Sue Peacock; Tom Morgan; Joann G Elmore; Donald L Weaver
Journal:  Histopathology       Date:  2016-09-23       Impact factor: 5.087

2.  Classifying Anal Intraepithelial Neoplasia 2 Based on LAST Recommendations.

Authors:  Yuxin Liu; W Glenn McCluggage; Teresa M Darragh; Wenxin Zheng; Jennifer M Roberts; Kay J Park; Pei Hui; Morgan Blakely; Keith Sigel; Michael M Gaisa
Journal:  Am J Clin Pathol       Date:  2021-05-18       Impact factor: 2.493

3.  Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel.

Authors:  Kimberly H Allison; Lisa M Reisch; Patricia A Carney; Donald L Weaver; Stuart J Schnitt; Frances P O'Malley; Berta M Geller; Joann G Elmore
Journal:  Histopathology       Date:  2014-04-02       Impact factor: 5.087

4.  [Human papillomaviruses in the pathogenesis of intraepithelial neoplasia (AIN) and carcinoma of the anus].

Authors:  M von Knebel Doeberitz; M Reuschenbach
Journal:  Hautarzt       Date:  2010-01       Impact factor: 0.751

5.  Expression of microRNAs 16, 20a, 150 and 155 in anal squamous intraepithelial lesions from high-risk groups.

Authors:  Andreia Albuquerque; Mara Fernandes; Oliver Stirrup; Ana Luísa Teixeira; Joana Santos; Marta Rodrigues; Elisabete Rios; Guilherme Macedo; Rui Medeiros
Journal:  Sci Rep       Date:  2019-02-06       Impact factor: 4.379

Review 6.  Comparing and contrasting clinical consensus and guidelines for anal intraepithelial neoplasia in different geographical regions.

Authors:  Danielle R L Brogden; Micol E E Lupi; Oliver J Warren; Christos Kontovounisios; Sarah C Mills
Journal:  Updates Surg       Date:  2021-09-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.